2-[[2-Amino-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoic acid

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 2-[[2-Amino-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoic acid
• 化学式: C₁₂H₂₆N₈O₃
• 分子量: 330.39
• InChiKey: OMLWNBVRVJYMBQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -6.5
• 重原子数：
  23
• 可旋转键数：
  11
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  221
• 氢给体数：
  7
• 氢受体数：
  6

文献信息

• COMPOUNDS AND METHODS FOR DELIVERY OF PROSTACYCLIN ANALOGS
  申请人：United Therapeutics Corporation

  公开号：US20150259274A1

  公开（公告）日：2015-09-17

  This invention pertains generally to prostacyclin formulations and methods for their use in promoting vasodilation, inhibiting platelet aggregation and thrombus formation, stimulating thrombolysis, inhibiting cell proliferation (including vascular remodeling), providing cytoprotection, preventing atherogenesis and inducing angiogenesis.

  这项发明通常涉及前列环素配方及其在促进血管舒张、抑制血小板聚集和血栓形成、刺激溶栓、抑制细胞增殖（包括血管重塑）、提供细胞保护、预防动脉粥样硬化和诱导血管生成方面的用途方法。
• Compounds and methods for delivery of prostacyclin analogs
  申请人：Phares Ken

  公开号：US20050085540A1

  公开（公告）日：2005-04-21

  This invention pertains generally to prostacyclin analogs and methods for their use in promoting vasodilation, inhibiting platelet aggregation and thrombus formation, stimulating thrombolysis, inhibiting cell proliferation (including vascular remodeling), providing cytoprotection, preventing atherogenesis and inducing angiogenesis. Generally, the compounds and methods of the present invention increase the oral bioavailability and circulating concentrations of treprostinil when administered orally. Compounds of the present invention have the following formula:

  本发明涉及前列环素类似物及其在促进血管扩张、抑制血小板聚集和血栓形成、刺激溶栓、抑制细胞增殖（包括血管重塑）、提供细胞保护、预防动脉粥样硬化和诱导血管生成方面的应用方法。一般而言，本发明的化合物和方法在口服给药时增加了曲前列素的口服生物利用度和循环浓度。本发明的化合物具有以下公式：
• PRODUCT FOR TRANSFORMATION OF A TOXIC CORROSIVE OR ENVIRONMENTALLY-NOXIOUS LIQUID PRODUCT INTO A NON-CORROSIVE OR NON-NOXIOUS RESIDUE
  申请人：Meyer Marie-Claude

  公开号：US20090224202A1

  公开（公告）日：2009-09-10

  The invention relates to a product for transformation of a toxic corrosive or environmentally-noxious product into a non-corrosive or non-noxious residue, comprising at least one amphoteric agent, at least one lipophilic absorbent, at least one hydrophilic absorbent and at least one binary coloured indicator, selected from the group of the following mixtures: Nile blue/alizarin red, alizarin yellow/alizarin red, thymolphthalein/methyl red, phenolphthalein/methyl red and tropaeolin OO/thymol blue and optionally an additive selected from the group comprising charge agents, granulation agents, anti-static agents and mixtures thereof.

  本发明涉及一种产品，用于将有毒腐蚀性或对环境有害的产品转化为非腐蚀性或非有害残留物，包括至少一种两性离子表面活性剂，至少一种亲脂性吸附剂，至少一种亲水性吸附剂和至少一种二元色指示剂，选择自以下混合物组：尼罗蓝/茜素红、茜素黄/茜素红、酚酞酸甲酯/甲基红、酚酞酸/甲基红和番红花OO/酚酞蓝，以及可选的添加剂，选择自包括电荷剂、造粒剂、抗静电剂和其混合物的组中。
• Compositions and Methods Relating to Ionic Salts of Peptides
  申请人：THETIS PHARMACEUTICALS LLC

  公开号：US20160107985A1

  公开（公告）日：2016-04-21

  The present invention relates to compounds of Formula I, compositions containing same, and methods of use.

  本发明涉及式I的化合物，含有该化合物的组合物以及使用方法。
• Novel peptides
  申请人：NOVO NORDISK A/S

  公开号：EP0194864A2

  公开（公告）日：1986-09-17

  Insulin derivatives having a charge which is positive compared with the charge of human insulin at neutral pH, can be used to prepare solutions having prolonged insulin action, In the novel insulin derivatives, a basic amino acid has been substituted in the B27-position and/or a neutral amino acid has been inserted in the A4-, A17-, B13- and/or B21-position. Furthermore, the C-terminal carboxyl group of the B-chain has been blocked with an amido or ester residue.

  在新型胰岛素衍生物中，B27 位的碱性氨基酸已被取代，并且/或者在 A4、A17、B13 和/或 B21 位插入了中性氨基酸。此外，B 链的 C 端羧基被氨基或酯残基阻断。